Accuracy of positron emission tomography and computed tomography (PET/CT) in detecting nodal metastasis according to histology of non-small cell lung cancer

2019 ◽  
Vol 71 (4) ◽  
pp. 741-746
Author(s):  
David E. Smith ◽  
Julian Fernandez Aramburu ◽  
Alejandro Da Lozzo ◽  
Juan A. Montagne ◽  
Enrique Beveraggi ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Small Cell Lung Cancer ◽  
Nodal Metastasis ◽  
Small Cell ◽  
Emission Tomography ◽  
Small Cell Lung ◽  
Positron Emission ◽  
Pet Ct

The role of positron emission tomography combined with computed tomography in the diagnosis and evaluation of treatment effectiveness of non-small cell lung cancer

2016 ◽  
Vol 21 (3) ◽  
pp. 160-164
Author(s):  
Nadezhda A. Meshcheryakova ◽  
M. B Dolgushin ◽  
M. M Davydov ◽  
K. K Laktionov ◽  
A. A Odzharova ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Lymph Nodes ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Emission Tomography ◽  
Small Cell Lung ◽  
Positron Emission ◽  
Pet Ct

Single photon emission computed tomography (SPECT) with the use of various tumor-tropic radiopharmaceutical preparations (RFP) has shown its effectiveness in the identification of tumor process in the lungs and metastatic lesions of mediastinal lymph nodes. In lung cancer such RFPs as Technetium-99m methoxy isobutyl isonitrile (MIBI) I) and 99mTc-depreotid got the largest traction. Increasingly frequently for the initial assessment of the prevalence ofprimary non-small cell lung cancer (NSCLC) there was used positron emission tomography combined with computed tomography (PET/CT) with 2-[18F]Fluoro-2-deoxy-d-glucose ([18F]FDG). The combined PET/CT image consider metabolic and morphological data, that allows to localize precisely the dissemination of the process and is used for the confirmation of the stage, detection of metabolically active extrathoracic lymph nodes, including those of the standard size (

scholarly journals Budget impact from the incorporation of positron emission tomography – computed tomography for staging lung cancers

2015 ◽  
Vol 49 (0) ◽  
pp. 1-10 ◽  
Author(s):  
Aline Navega Biz ◽  
Rosângela Caetano
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Small Cell Lung Cancer ◽  
Budget Impact ◽  
Small Cell ◽  
Emission Tomography ◽  
Small Cell Lung ◽  
Positron Emission ◽  
Pet Ct

<sec><title>OBJECTIVE</title><p> To estimate the budget impact from the incorporation of positron emission tomography (PET) in mediastinal and distant staging of non-small cell lung cancer.</p></sec><sec><title>METHODS</title><p> The estimates were calculated by the epidemiological method for years 2014 to 2018. Nation-wide data were used about the incidence; data on distribution of the disease´s prevalence and on the technologies’ accuracy were from the literature; data regarding involved costs were taken from a micro-costing study and from Brazilian Unified Health System (SUS) database. Two strategies for using PET were analyzed: the offer to all newly-diagnosed patients, and the restricted offer to the ones who had negative results in previous computed tomography (CT) exams. Univariate and extreme scenarios sensitivity analyses were conducted to evaluate the influence from sources of uncertainties in the parameters used.</p></sec><sec><title>RESULTS</title><p> The incorporation of PET-CT in SUS would imply the need for additional resources of 158.1 BRL (98.2 USD) million for the restricted offer and 202.7 BRL (125.9 USD) million for the inclusive offer in five years, with a difference of 44.6 BRL (27.7 USD) million between the two offer strategies within that period. In absolute terms, the total budget impact from its incorporation in SUS, in five years, would be 555 BRL (345 USD) and 600 BRL (372.8 USD) million, respectively. The costs from the PET-CT procedure were the most influential parameter in the results. In the most optimistic scenario, the additional budget impact would be reduced to 86.9 BRL (54 USD) and 103.8 BRL (64.5 USD) million, considering PET-CT for negative CT and PET-CT for all, respectively.</p></sec><sec><title>CONCLUSIONS</title><p> The incorporation of PET in the clinical staging of non-small cell lung cancer seems to be financially feasible considering the high budget of the Brazilian Ministry of Health. The potential reduction in the number of unnecessary surgeries may cause the available resources to be more efficiently allocated.</p></sec>

Volumetric and dosimetric comparison of computerised radiotherapy treatment plan between using positron emission tomography/computed tomography (PET/CT) and CT images for target delineation in non-small cell lung cancer patients

2016 ◽  
Vol 15 (2) ◽  
pp. 161-169
Author(s):  
Sanphat Sangudsup ◽  
Tawika Kaewchur ◽  
Waralee Teeyasoontranon ◽  
Pitchayaponne Klunklin ◽  
Nisa Chawapun ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Organs At Risk ◽  
Small Cell ◽  
Emission Tomography ◽  
Target Coverage ◽  
Small Cell Lung ◽  
Positron Emission ◽  
Pet Ct

AbstractPurposeTo compare intensity-modulated radiation therapy (IMRT) treatment planning between using positron emission tomography/computed tomography (PET/CT) and CT for target volume delineation in patients with non-small cell lung cancer (NSCLC).MethodsNine NSCLC patients with PET/CT images were enrolled into this study. Gross tumour volumes (GTVs) were delineated by the PET visual assessment (PETvis), the automated PET (PETauto), standardised uptake value (SUV)>2·5 (PET2·5) and threshold 40% SUVmax (PET40), and CT-based method. For each patient, two IMRT treatment plans based on CT and PET/CT delineation were performed. The target coverage and the dose–volume parameters for organs at risk were analysed.ResultsThe PETauto referred to PET40 when SUVmax<7 and PET2·5 when SUVmax≥7. The mean GTVs were 15·04, 15·7 and 15·14 cc for PETauto, PETvis and CT based, respectively. The GTV of PETauto was not different from PETvis (p=0·441) and CT based (p=0·594). Based on CT delineation in IMRT planning, only 34% of the cases had sufficient PET/CT planning target volumes coverage, whereas the organs at risk dose parameters were not statistically significant (p>0·05).ConclusionsPET/CT enables more accurate assessment of tumour delineation for NSCLC, therefore improve target coverage in IMRT plan.

Sign in / Sign up

Export Citation Format

Share Document